Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Outlook Therapeutics (OTLK)
NASDAQ:OTLK
Holding OTLK?
Track your performance easily
OTLK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.10 - $18.00
Previous Close$6.04
Volume317.46K
Average Volume (3M)219.44K
Market Cap
$142.88M
Enterprise Value$143.58M
Total Cash (Recent Filing)$32.02M
Total Debt (Recent Filing)$32.72M
Price to Earnings (P/E)―
Beta<0.01
Next Earnings
Dec 19, 2024EPS Estimate
-$0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.75
Shares Outstanding23,655,636
10 Day Avg. Volume310,493
30 Day Avg. Volume219,442
Standard Deviation0.37
R-Squared0.00830
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)-1.71
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.01
Forecast
1Y Price Target
$34.50Price Target Upside481.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Outlook Therapeutics News
Bulls Say, Bears Say
Bulls Say
Commercial LaunchFollowing the approval of Lytenava in the EU and UK, Outlook continues to prepare for the commercial launch.
Financial PerformanceOutlook Therapeutics posted a non-GAAP loss per share of $0.83, below the estimate of $0.93 loss per share and the street consensus of $1.03 loss per share.
Market OpportunitiesThe commercial market for treating retinal diseases is sizable with approved products generating annual sales of ~$15 billion.
Bears Say
Market CompetitionManagement noted there has been greater price compression in the branded anti-VEGF market in Europe (€400-€1,000 per dose in the EU versus $2,000 in the US market).
Product Quality ConcernsCompounded bevacizumab leaves much to be desired, as there are prevailing concerns surrounding manufacturing quality with implications ranging from diminished efficacy to potentially life-changing adverse events.
Regulatory IssuesThe FDA issued a Complete Response Letter for the BLA for ONS-5010, citing several CMC issues and open observations from pre-approval manufacturing inspections.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
OTLK FAQ
What was Outlook Therapeutics’s price range in the past 12 months?
Outlook Therapeutics lowest stock price was $4.10 and its highest was $18.00 in the past 12 months.
What is Outlook Therapeutics’s market cap?
Currently, no data Available
When is Outlook Therapeutics’s upcoming earnings report date?
Outlook Therapeutics’s upcoming earnings report date is Dec 19, 2024 which is in 90 days.
How were Outlook Therapeutics’s earnings last quarter?
Outlook Therapeutics released its earnings results on Aug 14, 2024. The company reported -$0.83 earnings per share for the quarter, beating the consensus estimate of -$1.033 by $0.203.
Is Outlook Therapeutics overvalued?
According to Wall Street analysts Outlook Therapeutics’s price is currently Undervalued.
Does Outlook Therapeutics pay dividends?
Outlook Therapeutics does not currently pay dividends.
What is Outlook Therapeutics’s EPS estimate?
Outlook Therapeutics’s EPS estimate is -$0.81.
How many shares outstanding does Outlook Therapeutics have?
Outlook Therapeutics has 23,655,636 shares outstanding.
What happened to Outlook Therapeutics’s price movement after its last earnings report?
Outlook Therapeutics reported an EPS of -$0.83 in its last earnings report, beating expectations of -$1.033. Following the earnings report the stock price went down -5.29%.
Which hedge fund is a major shareholder of Outlook Therapeutics?
Among the largest hedge funds holding Outlook Therapeutics’s share is Woodline Partners LP. It holds Outlook Therapeutics’s shares valued at 1M.
---
Outlook Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.50 (481.79% Upside)
$34.50 (481.79% Upside)
Blogger Sentiment
Bullish
OTLK Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 150.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
40.39%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.95%
Trailing 12-Months
Company Description
Outlook Therapeutics
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the identification, development, manufacture, and commercialization of complex biosimilar therapeutics. It focuses on monoclonal antibodies, in the disease areas of immunology and oncology. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Cranbury, NJ.
---
OTLK Earnings Call
Q3 2024
0:00 / 0:00
---
OTLK Stock 12 Month Forecast
Average Price Target
$34.50
▲(481.79% Upside)
Technical Analysis
Best Analysts Covering OTLK
1 Year
1 Year Success Rate
2/8 ratings generated profit
1 Year Average Return
-11.68%
reiterated a buy rating 20 days ago
Copying Edward Woo's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -11.68% per trade.
---